Sulphonylureas in the management of type 2 diabetes: To be or not to be?

Sulphonylureas (SUs) for a long time occupied an essential role in the management of type 2 diabetes (T2D) as an alternative or a complement to metformin. However, the launch of new oral antidiabetic drugs (OADs), firstly DPP-4 inhibitors (gliptins) and more recently SGLT2 inhibitors (gliflozins), has markedly changed the scene. Indeed, in contrast to SUs, these new OADs (of course more expensive) offer the advantage of a very low risk of...